NASDAQ: PPBTPurple Biotech Ltd Stock
$2.84+0.33 (+13.15%)
Updated Apr 17, 2025
PPBT Price
$2.84
Fair Value Price
$0.21
Market Cap
$146.86M
52 Week Low
$2.00
52 Week High
$20.60
P/E
-0.06x
P/B
4.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$7.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$14M
Beta
0.84
Next Earnings
May 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PPBT Overview
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PPBT's potential to beat the market
- PPBT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PPBT
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important PPBT news, forecast changes, insider trades & much more!
PPBT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PPBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PPBT ($2.84) is overvalued by 1,263.39% relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PPBT ($2.84) is not significantly undervalued (1,263.39%) relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PPBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PPBT due diligence checks available for Premium users.
Valuation
PPBT fair value
Fair Value of PPBT stock based on Discounted Cash Flow (DCF)
Price
$2.84
Fair Value
$0.21
Overvalued by
1,263.39%
PPBT ($2.84) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PPBT ($2.84) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PPBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PPBT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
-177.72x
Market
27.98x
PPBT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.47x
Industry
4.05x
PPBT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PPBT's financial health
Profit margin
Revenue
$0.0
Net Income
$410.0k
Profit Margin
0%
PPBT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$37.0M
Liabilities
$4.1M
Debt to equity
0.13
PPBT's short-term assets ($8.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PPBT's short-term assets ($8.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PPBT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PPBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$38.0k
Financing
$3.9M
PPBT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PPBT vs Biotech Stocks
Purple Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.